Aceragen | Passivo Circulante



Current Liabilities Alterar Data
Abbott USD 13B 1.15B 2025-03
Alnylam Pharmaceuticals USD 1.08B 110.65M 2025-03
Amgen USD 23.01B 91M 2025-03
Biogen USD 5.3B 231.4M 2025-03
BioMarin Pharmaceutical USD 628.21M 21.22M 2025-03
Cipla INR 54.84B 291.6M 2025-03
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 20.16M 7.6M 2024-12
CSL USD 6.07B 1.12B 2024-12
Dynavax Technologies USD 68.38M 10.26M 2025-03
Eli Lilly USD 30.07B 1.69B 2025-03
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 20.83B 866M 2025-03
Grifols EUR 2.16B 199.43M 2024-12
Merck USD 25.17B 3.25B 2025-03
Pfizer USD 36.45B 6.54B 2025-03
Roche Holding CHF 27.02B 424M 2024-12
Sarepta Therapeutics USD 605.59M 126.1M 2025-03
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
X T L Biopharmaceuticals USD 2.21M 260K 2024-12


Aceragen Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Jul 2025.